J López-Torrecilla1,2, D González Sanchis3, D Granero Cabañero4, E García Miragall3, P Almendros Blanco3, A Hernandez Machancoses3, L Brualla González4, J Pastor Peidro3, J C Gordo Partearroyo3, J Rosello Ferrando4. 1. Department of Radiation Oncology-ERESA, Hospital General Universitario de Valencia, Av. Tres Cruces, 2, 46014, Valencia, Spain. jltorrecilla@eresa.com. 2. Servicio Oncología Radioterápica-ERESA, Hospital General Valencia, Av. Tres Cruces, 2, 46014, Valencia, Spain. jltorrecilla@eresa.com. 3. Department of Radiation Oncology-ERESA, Hospital General Universitario de Valencia, Av. Tres Cruces, 2, 46014, Valencia, Spain. 4. Radiotherapy Physics Department-ERESA, Hospital General Universitario de Valencia, Av. Tres Cruces, 2, 46014, Valencia, Spain.
Abstract
PURPOSE: RENORT is a novel data mining application developed to extract relevant clinical data from oncology information systems (OIS; ARIA and Mosaiq) used in radiation oncology (RO). METHODS/PATIENTS: We used RENORT to extract demographic and clinical data from the OIS of all patients treated at the RO Department at the General Hospital of Valencia during the year 2019. RESULTS: A total of 1158 treatments were performed. The female/male ratio was 39.3%/60.7%, with a mean age of 66 years. The mean waiting time between the treatment decision/proposal to the first visit was 10.1 days. Mean duration of the treatment preparation process was 21 days. Most patients (90.4%) completed treatment within the prescribed time ± 7 days. The most common sites/treatment types were: metastatic/palliative treatments (n = 300; 25.9%), breast (209; 18.0%), genitourinary (195; 16.8%), digestive (116; 10.0%), thoracic (104; 9.0%), head and neck (62; 5.4%), and skin cancer (51; 4.4%). The distribution according to treatment intent was as follows: palliative (n = 266; 23.0%), adjuvant curative (335; 28.9%), radical without adjuvant treatment (229; 19.8%), radical with concomitant treatment (188; 16.2%), curative neoadjuvant (70; 6.0%), salvage radiotherapy (61; 5.3%); and reirradiation (9; 0.8%). The most common treatment techniques were IMRT/VMAT with IGRT (n = 468; 40.4%), 3D-CRT with IGRT (421; 36.4%), SBRT (127; 11.0%), 2DRT (57; 4.9%), and SFRT (56; 4.8%). A mean of 15.9 fractions were administered per treatment. Hypofractionated schemes were used in 100% of radical intent breast and prostate cancer treatments. CONCLUSIONS: The RENORT application facilitates data retrieval from oncology information systems to allow for a comprehensive determination of the real role of radiotherapy in the treatment of cancer patients. This application is valuable to identify patterns of care and to assess treatment efficacy.
PURPOSE: RENORT is a novel data mining application developed to extract relevant clinical data from oncology information systems (OIS; ARIA and Mosaiq) used in radiation oncology (RO). METHODS/PATIENTS: We used RENORT to extract demographic and clinical data from the OIS of all patients treated at the RO Department at the General Hospital of Valencia during the year 2019. RESULTS: A total of 1158 treatments were performed. The female/male ratio was 39.3%/60.7%, with a mean age of 66 years. The mean waiting time between the treatment decision/proposal to the first visit was 10.1 days. Mean duration of the treatment preparation process was 21 days. Most patients (90.4%) completed treatment within the prescribed time ± 7 days. The most common sites/treatment types were: metastatic/palliative treatments (n = 300; 25.9%), breast (209; 18.0%), genitourinary (195; 16.8%), digestive (116; 10.0%), thoracic (104; 9.0%), head and neck (62; 5.4%), and skin cancer (51; 4.4%). The distribution according to treatment intent was as follows: palliative (n = 266; 23.0%), adjuvant curative (335; 28.9%), radical without adjuvant treatment (229; 19.8%), radical with concomitant treatment (188; 16.2%), curative neoadjuvant (70; 6.0%), salvage radiotherapy (61; 5.3%); and reirradiation (9; 0.8%). The most common treatment techniques were IMRT/VMAT with IGRT (n = 468; 40.4%), 3D-CRT with IGRT (421; 36.4%), SBRT (127; 11.0%), 2DRT (57; 4.9%), and SFRT (56; 4.8%). A mean of 15.9 fractions were administered per treatment. Hypofractionated schemes were used in 100% of radical intent breast and prostate cancer treatments. CONCLUSIONS: The RENORT application facilitates data retrieval from oncology information systems to allow for a comprehensive determination of the real role of radiotherapy in the treatment of cancerpatients. This application is valuable to identify patterns of care and to assess treatment efficacy.
Entities:
Keywords:
Cancer; Pattern of care; RENORT; Radiotherapy
Authors: R Esco; A Palacios; J Pardo; A Biete; J A Carceller; C Veiras; G Vazquez Journal: Int J Radiat Oncol Biol Phys Date: 2003-06-01 Impact factor: 7.038
Authors: Amalia Palacios Eito; Sonia García Cabezas; Pilar Font Ugalde; Eleonor Rivin del Campo; Ana Otero Romero; María del Mar Pérez Martín; Juan Manuel Roldán Arjona; María Martínez Paredes Journal: Radiother Oncol Date: 2012-11-28 Impact factor: 6.280
Authors: Josep M Borras; Yolande Lievens; Peter Dunscombe; Mary Coffey; Julian Malicki; Julieta Corral; Chiara Gasparotto; Noemie Defourny; Michael Barton; Rob Verhoeven; Liesbeth van Eycken; Maja Primic-Zakelj; Maciej Trojanowski; Primoz Strojan; Cai Grau Journal: Radiother Oncol Date: 2015-05-14 Impact factor: 6.280
Authors: Benjamin D Smith; Jennifer R Bellon; Rachel Blitzblau; Gary Freedman; Bruce Haffty; Carol Hahn; Francine Halberg; Karen Hoffman; Kathleen Horst; Jean Moran; Caroline Patton; Jane Perlmutter; Laura Warren; Timothy Whelan; Jean L Wright; Reshma Jagsi Journal: Pract Radiat Oncol Date: 2018-03-12
Authors: J Jaén Olasolo; E Alonso Redondo; J Expósito Hernández; M D de las Peñas Cabrera; P Cabrera Roldán Journal: Clin Transl Oncol Date: 2007-12 Impact factor: 3.405
Authors: Patrick A Kupelian; Twyla R Willoughby; Chandana A Reddy; Eric A Klein; Arul Mahadevan Journal: Int J Radiat Oncol Biol Phys Date: 2007-06-04 Impact factor: 7.038
Authors: Anna Wilkins; Helen Mossop; Isabel Syndikus; Vincent Khoo; David Bloomfield; Chris Parker; John Logue; Christopher Scrase; Helen Patterson; Alison Birtle; John Staffurth; Zafar Malik; Miguel Panades; Chinnamani Eswar; John Graham; Martin Russell; Peter Kirkbride; Joe M O'Sullivan; Annie Gao; Clare Cruickshank; Clare Griffin; David Dearnaley; Emma Hall Journal: Lancet Oncol Date: 2015-10-28 Impact factor: 41.316